| Drug Name | (Xgeva® (Denosumab |
|---|---|
| Drug Class |
Immunosuppressant
|
| Risk minimization type |
Patient Card
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Oncology
Musculoskeletal Diseases
|
| Risk |
Safety information about risk of osteonecrosis of the jaw (ONJ) and Multiple Vertebral Fractures (MVF) following treatment discontinuation |
| Patient card |
|
| Dear Healthcare provider letter DHPC |
|